FUBIMINA
Synthetic cannabinoid of the benzimidazole class, bound to CB1 and CB2 receptors, classified as a narcotic in France.
C₂₃H₂₁FN₂O
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
Data sheet
Names
- IUPAC name
- [1-(5-fluoropentyl)benzimidazol-2-yl]-naphthalen-1-ylmethanone
- Other names
- BIM-2201 · BZ-2201 · FTHJ · (1-(5-Fluoropentyl)benzimidazol-2-yl)-(1-naphthyl)methanone
Identifiers
- Formula
- C₂₃H₂₁FN₂O
- Molar mass
- 360.40 g/mol
- PubChem CID
- 124519316(new tab)
- InChIKey
- KUESSZMROAFKQJ-UHFFFAOYSA-N
Class
- Family
- Synthetic cannabinoid (SCRA)
- First described
- 2013
Updated on
Receptors and activity
- CB1AgonistKi 502 nM (Schoeder et coll., 2018)50 out of 100
- CB2AgonistKi 99,0 nM (Schoeder et coll., 2018)65 out of 100
Subjective signature
- Calm
- 8 out of 100
- Relaxation of body and mind; reduced mental noise without marked drowsiness.
- Clarity
- 5 out of 100
- Sustained attention and clear thinking; functional lucidity, not euphoria.
- High
- 20 out of 100
- Euphoria and sensory intensity; altered perception of time and space.
- Appetite
- 10 out of 100
- Stimulation of hunger and of taste appreciation (the “munchies” effect).
- Sleep
- 15 out of 100
- Sedative effect: aids sleep onset and the continuity of deep sleep.
Pharmacology
FUBIMINA, also designated BIM-2201, is a synthetic cannabinoid of the benzimidazole class, a fluoro derivative of BIM-018 and an isomer of THJ-2201. Schoeder et al. (2018) measure an affinity of 502 nM at CB1 and of 99.0 nM at CB2. Wiley et al. (2015) describe it as a full agonist in the [35S]GTPγS assay and report, in mice, reduced locomotor activity, antinociception, hypothermia and catalepsy. Schoeder et al. observe only a partial activation of both receptors at 10 µM. First detected in 2013, it is expressly listed among the narcotics in France. No human data are published in the sources consulted.
Key sources.
- Wiley et coll., AB-CHMINACA, AB-PINACA et FUBIMINA chez la souris : affinité et puissance, J Pharmacol Exp Ther 2015 (new tab)PMID 26105953
- Diao et coll., distinguer la FUBIMINA de son isomère THJ-2201 : métabolisme dans les hépatocytes humains, Forensic Toxicol 2016 (new tab)PMID 27547265
- Schoeder et coll., nouveaux constituants du « Spice » : évaluation pharmacologique des cannabinoïdes de synthèse indole, indazole, benzimidazole et carbazole, Forensic Toxicol 2018 (new tab)PMID 29963207
- ANSM · Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026, annexe IV (new tab)
- Légifrance · Arrêté du 3 octobre 2017 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants (new tab)
- OICS · Liste verte des substances psychotropes sous contrôle international, édition 2026 (FUBIMINA non inscrite) (new tab)
- PubChem · CID 124519316, FUBIMINA (new tab)
History
- Source
- Entirely synthetic molecule. It was first detected in 2013 in herbal-type products bought online, according to Diao et al. (2016), who cite Uchiyama et al. It is easily accessible online and is designated by several names: FUBIMINA, BIM-2201, BZ-2201 and FTHJ. Scheduled in Japan since August 2014 (Diao et al., 2016), it is the isomer of THJ-2201, from which it is distinguished by mass spectrometry.
Origin (pharmaceutical research → illicit market)
No biosynthetic pathway: FUBIMINA does not derive from hemp. It is a synthetic cannabinoid, obtained by laboratory chemistry, of the acylated benzimidazole class, unrelated to the terpenophenols of the plant.
Legal framework
- European Union
No harmonised European Union control measure was found in the sources consulted for this record: control falls under the national legislation of the Member States.
- France
Narcotic in France. FUBIMINA is expressly listed in annex IV of the consolidated list of narcotics (updated 16 February 2026), in the block of the following cannabinoids, together with their isomers, stereoisomers, esters, ethers and salts. This listing stems from the order of 3 October 2017 amending the order of 22 February 1990.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
References
- Wiley et coll., AB-CHMINACA, AB-PINACA et FUBIMINA chez la souris : affinité et puissance, J Pharmacol Exp Ther 2015 (new tab)PMID 26105953
- Diao et coll., distinguer la FUBIMINA de son isomère THJ-2201 : métabolisme dans les hépatocytes humains, Forensic Toxicol 2016 (new tab)PMID 27547265
- Schoeder et coll., nouveaux constituants du « Spice » : évaluation pharmacologique des cannabinoïdes de synthèse indole, indazole, benzimidazole et carbazole, Forensic Toxicol 2018 (new tab)PMID 29963207
- ANSM · Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026, annexe IV (new tab)
- Légifrance · Arrêté du 3 octobre 2017 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants (new tab)
- OICS · Liste verte des substances psychotropes sous contrôle international, édition 2026 (FUBIMINA non inscrite) (new tab)
- PubChem · CID 124519316, FUBIMINA (new tab)
Structured data
- SMILES
- C1=CC=C2C(=C1)C=CC=C2C(=O)C3=NC4=CC=CC=C4N3CCCCCF
- InChIKey
- KUESSZMROAFKQJ-UHFFFAOYSA-N
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.